Orexo AB, announces that the United States Patent and Trademark Office has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.
Orexo AB, announces that the United States Patent and Trademark Office has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.